Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells.

Cannizzo ES, Cerrone M, Merlini E, van Wilgenburg B, Swadling L, Ancona G, De Bona A, d'Arminio Monforte A, Klenerman P, Marchetti G.

Eur J Immunol. 2019 Jul;49(7):1127-1129. doi: 10.1002/eji.201948152. Epub 2019 May 14. No abstract available.

PMID:
30985000
2.

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L.

Front Immunol. 2019 Jan 18;9:3175. doi: 10.3389/fimmu.2018.03175. eCollection 2018.

3.

Circulating and intrahepatic antiviral B cells are defective in hepatitis B.

Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK.

J Clin Invest. 2018 Oct 1;128(10):4588-4603. doi: 10.1172/JCI121960. Epub 2018 Aug 9.

4.

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.

Easom NJW, Stegmann KA, Swadling L, Pallett LJ, Burton AR, Odera D, Schmidt N, Huang WC, Fusai G, Davidson B, Maini MK.

Front Immunol. 2018 May 9;9:1009. doi: 10.3389/fimmu.2018.01009. eCollection 2018.

5.

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines.

Gordon CL, Lee LN, Swadling L, Hutchings C, Zinser M, Highton AJ, Capone S, Folgori A, Barnes E, Klenerman P.

Cell Rep. 2018 Apr 17;23(3):768-782. doi: 10.1016/j.celrep.2018.03.074.

6.

Targeted reconstruction of T cell receptor sequence from single cell RNA-seq links CDR3 length to T cell differentiation state.

Afik S, Yates KB, Bi K, Darko S, Godec J, Gerdemann U, Swadling L, Douek DC, Klenerman P, Barnes EJ, Sharpe AH, Haining WN, Yosef N.

Nucleic Acids Res. 2017 Sep 19;45(16):e148. doi: 10.1093/nar/gkx615.

7.

Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.

van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW.

Antiviral Res. 2017 Oct;146:139-145. doi: 10.1016/j.antiviral.2017.08.016. Epub 2017 Aug 24.

8.

IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection.

Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA, Schurich A, Swadling L, Gill US, Male V, Luong T, Gander A, Davidson BR, Kennedy PTF, Maini MK.

J Exp Med. 2017 Jun 5;214(6):1567-1580. doi: 10.1084/jem.20162115. Epub 2017 May 19.

9.

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.

Stelma F, van der Ree MH, Sinnige MJ, Brown A, Swadling L, de Vree JML, Willemse SB, van der Valk M, Grint P, Neben S, Klenerman P, Barnes E, Kootstra NA, Reesink HW.

Hepatology. 2017 Jul;66(1):57-68. doi: 10.1002/hep.29148. Epub 2017 Jun 7.

10.

Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus.

Brown A, Halliday JS, Swadling L, Madden RG, Bendall R, Hunter JG, Maggs J, Simmonds P, Smith DB, Vine L, McLaughlin C, Collier J, Bonsall D, Jeffery K, Dunachie S, Klenerman P, Izopet J, Kamar N, Dalton HR, Barnes E.

Hepatology. 2016 Dec;64(6):1934-1950. doi: 10.1002/hep.28819. Epub 2016 Oct 28.

11.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E.

Vaccines (Basel). 2016 Aug 2;4(3). pii: E27. doi: 10.3390/vaccines4030027.

12.

Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.

Bolinger B, Sims S, Swadling L, O'Hara G, de Lara C, Baban D, Saghal N, Lee LN, Marchi E, Davis M, Newell E, Capone S, Folgori A, Barnes E, Klenerman P.

Cell Rep. 2015 Nov 24;13(8):1578-88. doi: 10.1016/j.celrep.2015.10.034. Epub 2015 Nov 12.

13.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Hepatology. 2016 May;63(5):1455-70. doi: 10.1002/hep.28294. Epub 2016 Jan 22.

14.

CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.

Fergusson JR, Hühn MH, Swadling L, Walker LJ, Kurioka A, Llibre A, Bertoletti A, Holländer G, Newell EW, Davis MM, Sverremark-Ekström E, Powrie F, Capone S, Folgori A, Barnes E, Willberg CB, Ussher JE, Klenerman P.

Mucosal Immunol. 2016 Mar;9(2):401-13. doi: 10.1038/mi.2015.69. Epub 2015 Jul 29.

15.

CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.

Fergusson JR, Smith KE, Fleming VM, Rajoriya N, Newell EW, Simmons R, Marchi E, Björkander S, Kang YH, Swadling L, Kurioka A, Sahgal N, Lockstone H, Baban D, Freeman GJ, Sverremark-Ekström E, Davis MM, Davenport MP, Venturi V, Ussher JE, Willberg CB, Klenerman P.

Cell Rep. 2014 Nov 6;9(3):1075-88. doi: 10.1016/j.celrep.2014.09.045. Epub 2014 Oct 23.

16.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Sci Transl Med. 2014 Nov 5;6(261):261ra153. doi: 10.1126/scitranslmed.3009185.

17.

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.

Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, Klenerman P, Barnes E.

Eur J Immunol. 2015 Jan;45(1):309-16. doi: 10.1002/eji.201444686. Epub 2014 Oct 30.

18.

Ever closer to a prophylactic vaccine for HCV.

Swadling L, Klenerman P, Barnes E.

Expert Opin Biol Ther. 2013 Aug;13(8):1109-24. doi: 10.1517/14712598.2013.791277. Epub 2013 May 7. Review.

19.

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P.

Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.

Supplemental Content

Loading ...
Support Center